Are You Trained For The Stem Cell Revolution
A company who specializes in the development and design of medical procedures and devices for the medicine market designated to regeneration is Biological Therapies, Inc. (BTI). Today they announced that their products have been successfully used to treat an Achilles tendon that was chronically injured; this was for with stem cell therapy.
Authored by founders of the Southlake, Texas Riordan-McKenna Institute, the Chief Medical Director at Biological Therapies, Dr. R. Wade McKenna as well as Dr. Neil H. Riordan who is Chief Scientific Officer, the case report released was titled; “The Treatment of Achilles tendon Which is Chronically Injured with Stem Cells from Autologous Bone Marrow Concentrate: A Case report.” (www.rmiclinic.com)
The case revolved around a female patient which was fifty six years old and had complaints about a knot in her left Achilles tendon which was very painful. Due to the pain, performing her daily activities even like shopping had become limited and she was unable to remain on her feet for over thirty minutes. There was a time in which she had been a recreational athlete and an active tennis player, it had however now been ten years since she had been able to jog or even play tennis.
She reported that she experienced extreme pain when walking and significant pain even while relaxing. She had gone to see countless physicians and for ten years had followed the standard treatment of anti-inflammatories and stretches. She had been offered multiple offers for invasive surgery which she turned down being as they could not guarantee her return to tennis.
When Dr. R. Wade McKenna examined her, he found a knot in the Achilles tendon that was large and palpable; it was very noticeable and extremely tender. After an MRI, the results showed hypertrophic changes which were severe along with a marked tendinopathy. A point of care stem cell therapy treatment was provided to the patient in Dr. McKenna´s office with the use of Biologic Therapies products and as an outpatient procedure.
Bone marrow from the tibia (shin) bone was drawn by the physician, the marrow was processed in a centrifuge to concentrate these stem cells as well as growth factors, the growth factors and stem cells were then injected into and around the Achilles tendon that was injured. Before the growth factors and stem cells were injected, in order to prevent pain, a local injection of anesthesia was provided. The patient reported that she felt little to no pain during the procedure as well as after.
After six weeks had elapsed, the patient reported minimal pain while walking and no pain at rest. After eight weeks had passed, the pain felt while walking was even less. The size of the knot went down around 50% of what it had been prior to the treatment and it was not as tender to touch. After ten weeks had elapsed, the patient reported that she was doing much better. Even more reduction in the size of the knot was proven with an MRI and there was even less pain. An MRI scan taken after thirty two weeks showed almost complete healing of the Achilles tendon that had been treated.
This case report has been published in the Official Journal of The Cure Alliance by the scientific journal, CELLR4. You can look over the report on the CELLR4 at the following webpage: http://www.cellr4.org/article/1100.
According to the CEO at Biological Therapies, Like Whalen, “This development is of extreme importance for Biological Therapies. This case report demonstrates that stem cell therapy can be used to effectively treat a chronic injury of the Achilles tendon; this is something that had not ever been documented before. This report also demonstrates that this type of injury can be treated with stem cell therapy in a physician’s office with the use of Biologic Therapies products and as a point of care outpatient procedure. Before there would have been a need for surgery and hospitalization, this is no longer the case.
“The fact that the scientific journal that this case report was published in is one of the most prestigious publications in the industry of regenerative medicine is another important aspect of this publication. Those who reviewed and approved this report and are member of the Journal Editorial Board of CELLR4 are in essence the who’s who of international regenerative medicine professionals. This helps to reinforce the position that Biologic Therapies has as global leaders in the world of regenerative medicine,” stated Whalen.
Editor and Chief, Camillo Ricordi leads the CELLR4 Editorial Board, he is from the Diabetes Research and Cell Transplant Center Institute located at the University of Miami which is in Miami, Florida. There are others in the editorial staff that are worth taking not of, for example; Antonio Pileggi who is Assistant Editor at the Diabetes Research and Cell Transplant Center Institute located at the University of Miami which is in Miami, Florida, Jianming Tan, Associate Editor for Asia at the Fuzhou General hospital in Xiamen University, China; and Arnold I. Caplan Assistant Board member from the Case Western Reserve University found in Cleveland, Ohio.
The technology used to isolate the human mesenchymal stem cells in adults (MSCs) from their bone marrow and preserve the multi-potency they have was developed and patented by Dr. Arnold Caplan and his colleagues in the late 1980´s. Human MSCs from adults are now able to turn into a variety of types of tissues which include cartilage, marrow, ligament, connective tissues, bone, muscle, tendon and adipocytes.
The CELLR4 Editorial board is made up of over one hundred physicians, researchers, scientists and educators from all over the world. You can find a complete listing if the Board members at http://www.cellr4.org/editorial-board.
CELLR4 is a scientific journal which focuses mainly on cellular replacement, repair, reprogramming, regeneration and differentiation. Its range is from important and innovative discoveries in this basic science to the transitional, clinical testing as well as delivering therapeutic options that are new.
This is international non-profit organization The Cure Alliance’s official journal and CELLR4 is used as a platform to discuss opportunities and challenges on the road of developing new treatments apart from the disease target. Commentaries and opinion papers are published by CELLR4 on legal, regulatory and ethical issues, they also provide information on funding opportunities and global collaborative platforms which are of interest in this field.
CELLR4 is also the official journal of another nonprofit organization that is international, the Fondazione Cure Alliance Onus which includes scientists, physicians, philanthropy and business leaders, patients and patient advocates with the goal of promoting collaborative efforts the world over, while looking into and working on resolving challenges and impediments on the road of developing cures for disease that now afflict the humankind. In this area, the publication is used as a platform for shared communications to discuss the opportunities and challenges on the road of developing new treatments.